文献速递妇科

靶向叶酸受体α的抗体偶联药物米维妥昔单抗索拉坦新联合帕博利珠单抗治疗铂耐药卵巢癌患者的安全性与疗效

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2025-07-22

在56例经多线治疗的铂耐药卵巢癌患者中,米维妥昔单抗索拉坦新(6 mg/kg,按调整理想体重)联合帕博利珠单抗(200 mg)每3周静脉给药,55例可评估者的客观缓解率为31%(95%CI 19-45),中位缓解持续时间8.0个月,中位无进展生存期4.2个月,安全性总体可耐受。

要点

  • 米维妥昔单抗索拉坦新联合帕博利珠单抗在经多线治疗的铂耐药卵巢癌中客观缓解率为31%。
  • 中位缓解持续时间8.0个月,中位无进展生存期4.2个月。
  • 治疗中出现肺炎发生率为25%,≥3级肺炎发生于2例(4%)参与者。

核心结论

  • 米维妥昔单抗索拉坦新联合帕博利珠单抗在经多线治疗的铂耐药卵巢癌患者中显示出抗癌疗效和可耐受的安全性,但疗效获益可能主要归因于米维妥昔单抗索拉坦新单药。

研究设计与样本

  • 在经多线治疗的铂耐药卵巢癌患者中开展剂量递增和扩展队列研究,评估米维妥昔单抗索拉坦新联合帕博利珠单抗的疗效与安全性。
  • 参与者为复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌,末次铂类治疗后≤6个月复发。
  • 给药方案为米维妥昔单抗索拉坦新6 mg/kg(按调整理想体重)联合帕博利珠单抗200 mg静脉给药,每3周一次。
  • 肿瘤叶酸受体α表达阈值:剂量递增队列为≥25%细胞≥2+膜染色强度,剂量扩展队列为≥50%细胞≥2+膜染色强度。
  • 共56例参与者接受双药治疗;中位年龄62岁(范围40-78)。

主要发现

  • 20%的参与者既往接受过3线全身治疗,43%既往接受过≥4线,43%有既往贝伐珠单抗暴露史,41%有既往PARP抑制剂暴露史。
  • 55例可评估疗效的参与者中,客观缓解率为31%(95%CI 19-45)。
  • 中位缓解持续时间为8.0个月(95%CI 4.2-未达到),中位无进展生存期为4.2个月(95%CI 2.8-5.6)。
  • 在既往接受多线治疗的患者中疗效持续存在。
  • 治疗中出现的不良事件与各药物已知特征一致;最常见为腹泻(所有级别57%,3级4%)、恶心(55%,5级?原文为5%)、疲乏(50%,2%)。

关键数值与推荐

  • 客观缓解率31%(95%CI 19-45),基于55例可评估疗效的参与者。
  • 中位缓解持续时间8.0个月(95%CI 4.2-未达到)。
  • 中位无进展生存期4.2个月(95%CI 2.8-5.6)。
  • 腹泻所有级别57%、3级4%;恶心所有级别55%、5%?原文为5%;疲乏所有级别50%、2%。
  • 治疗中出现肺炎25%,≥3级肺炎2例(4%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Evaluate the efficacy and safety of mirvetuximab soravtansine-gynx (MIRV) plus pembrolizumab in dose escalation and expansion cohorts of heavily pretreated patients with platinum-resistant ovarian cancer (PROC). METHODS: Participants with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer whose disease relapsed ≤6 months from last platinum-based treatment received MIRV (6 mg/kg adjusted ideal body weight) and pembrolizumab (200 mg) intravenously once every 3 weeks. Tumor FRα expression thresholds were ≥25 % (dose escalation cohort) and ≥50 % (dose expansion cohort) of cells with ≥2+ membrane staining intensity. The primary efficacy endpoint was objective response rate (ORR). Secondary endpoints included duration of response (DOR), progression-free survival (PFS), and safety. RESULTS: Fifty-six participants received the doublet. Median age was 62 years (range, 40-78). Twenty percent of participants had 3 prior lines of systemic treatment, 43 % had ≥4 prior lines, 43 % had prior bevacizumab exposure, and 41 % had prior PARP inhibitor exposure. Among 55 response-evaluable participants, ORR was 31 % (95 % CI, 19-45), median DOR was 8.0 months (95 % CI, 4.2-NR), and median PFS was 4.2 months (95 % CI, 2.8-5.6). Efficacy persisted in patients with multiple prior lines of treatment. Treatment-emergent adverse events were consistent with the profiles of each agent; the most common were diarrhea (all grades, 57 %; grade 3, 4 %), nausea (55 %; 5 %), and fatigue (50 %; 2 %). Treatment-emergent pneumonitis occurred in 25 % of participants, with grade ≥3 events occurring in 2 (4 %) participants. CONCLUSIONS: MIRV plus pembrolizumab demonstrated anti-cancer efficacy and a tolerable safety profile in heavily pretreated patients with PROC. However, the efficacy benefit may be mainly attributable to MIRV alone.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Matulonis UA, Vergote I, Moore KN, et al. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2025. PMID: 40700855. doi:10.1016/j.ygyno.2025.06.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。